$TDOC
Teladoc Health, Inc.

2023 Q2 Form 10-Q Financial Statement

#000155837023007654 Filed on May 02, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $652.4M $629.2M
YoY Change 10.13% 11.3%
Cost Of Revenue $190.5M $190.1M
YoY Change 4.42% 1.65%
Gross Profit $461.9M $439.1M
YoY Change 12.68% 16.07%
Gross Profit Margin 70.79% 69.79%
Selling, General & Admin $179.4M $345.4M
YoY Change 6.26% 111.59%
% of Gross Profit 38.84% 78.66%
Research & Development $87.31M $86.99M
YoY Change 8.02% -0.49%
% of Gross Profit 18.9% 19.81%
Depreciation & Amortization $75.47M $70.46M
YoY Change 25.59% 19.57%
% of Gross Profit 16.34% 16.05%
Operating Expenses $266.7M $502.2M
YoY Change 6.83% 100.35%
Operating Profit -$71.65M -$63.06M
YoY Change -97.69% -99.05%
Interest Expense $5.835M $3.648M
YoY Change -234.54% -166.57%
% of Operating Profit
Other Income/Expense, Net -$207.0K $4.907M
YoY Change -88.24% 577.76%
Pretax Income -$66.13M -$68.55M
YoY Change -97.87% -98.97%
Income Tax -$952.0K $681.0K
% Of Pretax Income
Net Earnings -$65.18M -$69.23M
YoY Change -97.9% -98.96%
Net Earnings / Revenue -9.99% -11.0%
Basic Earnings Per Share -$0.40 -$0.42
Diluted Earnings Per Share -$0.40 -$0.42
COMMON SHARES
Basic Shares Outstanding 163.7M 162.6M
Diluted Shares Outstanding 164.2M shares 162.9M

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $958.7M $888.6M
YoY Change 8.49% 5.91%
Cash & Equivalents $958.7M $888.6M
Short-Term Investments
Other Short-Term Assets $8.368M $136.3M
YoY Change 19.39% 2460.01%
Inventory $34.05M $45.80M
Prepaid Expenses $62.10M $77.53M
Receivables $215.2M $216.0M
Other Receivables $12.26M $0.00
Total Short-Term Assets $1.321B $1.287B
YoY Change 5.07% 6.51%
LONG-TERM ASSETS
Property, Plant & Equipment $30.39M $69.31M
YoY Change 10.91% 143.88%
Goodwill $1.073B $1.073B
YoY Change -77.91% -86.41%
Intangibles $1.784B $1.816B
YoY Change -4.7% -3.61%
Long-Term Investments
YoY Change
Other Assets $72.93M $63.99M
YoY Change 92.22% 140.31%
Total Long-Term Assets $2.995B $3.022B
YoY Change -56.24% -69.42%
TOTAL ASSETS
Total Short-Term Assets $1.321B $1.287B
Total Long-Term Assets $2.995B $3.022B
Total Assets $4.316B $4.309B
YoY Change -46.73% -61.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $16.07M $38.63M
YoY Change -82.97% -18.53%
Accrued Expenses $208.1M $235.5M
YoY Change 47.64% 84.44%
Deferred Revenue $107.4M
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $11.25M
YoY Change -11.19%
Total Short-Term Liabilities $383.4M $381.3M
YoY Change 3.21% 24.34%
LONG-TERM LIABILITIES
Long-Term Debt $1.537B $1.544B
YoY Change -0.29% 0.2%
Other Long-Term Liabilities $1.740M $41.79M
YoY Change 8.14% 2792.25%
Total Long-Term Liabilities $1.740M $1.586B
YoY Change 8.14% 109655.29%
TOTAL LIABILITIES
Total Short-Term Liabilities $383.4M $381.3M
Total Long-Term Liabilities $1.740M $1.586B
Total Liabilities $385.1M $2.018B
YoY Change 3.23% 554.89%
SHAREHOLDERS EQUITY
Retained Earnings -$15.14B -$15.08B
YoY Change 36.12% 87.92%
Common Stock $17.48B $17.41B
YoY Change 1.38% 1.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.295B $2.291B
YoY Change
Total Liabilities & Shareholders Equity $4.316B $4.309B
YoY Change -46.73% -61.15%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income -$65.18M -$69.23M
YoY Change -97.9% -98.96%
Depreciation, Depletion And Amortization $75.47M $70.46M
YoY Change 25.59% 19.57%
Cash From Operating Activities $101.2M $13.16M
YoY Change 9.42% -141.44%
INVESTING ACTIVITIES
Capital Expenditures $36.57M $45.62M
YoY Change -181.56% 1065.96%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities -$36.57M -$45.62M
YoY Change -18.44% 65.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.208M 3.353M
YoY Change -415.44% 19.07%
NET CHANGE
Cash From Operating Activities 101.2M 13.16M
Cash From Investing Activities -36.57M -45.62M
Cash From Financing Activities 4.208M 3.353M
Net Change In Cash 68.82M -29.12M
YoY Change 48.65% -48.47%
FREE CASH FLOW
Cash From Operating Activities $101.2M $13.16M
Capital Expenditures $36.57M $45.62M
Free Cash Flow $64.61M -$32.47M
YoY Change -52.94% -8.95%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.42
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-41.58
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
162922691
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
160532301
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
162840360
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
163919394
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001477449
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://www.teladoc.com/20230331#AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent
CY2023Q1 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P9M
CY2023Q1 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-37477
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
TELADOC HEALTH, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
04-3705970
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
2 Manhattanville Road
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 203
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Purchase
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10577
CY2023Q1 dei City Area Code
CityAreaCode
203
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
635-2002
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2023Q1 dei Trading Symbol
TradingSymbol
TDOC
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NYSE
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
163670601
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
888579000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
918182000
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
6106000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
4324000
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
215981000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
210554000
CY2023Q1 us-gaap Inventory Net
InventoryNet
45801000
CY2022Q4 us-gaap Inventory Net
InventoryNet
56342000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
136346000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
130310000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
1286707000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
1315388000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
29791000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
29641000
CY2023Q1 us-gaap Goodwill
Goodwill
1073190000
CY2022Q4 us-gaap Goodwill
Goodwill
1073190000
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1815948000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1836765000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
39518000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
41831000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
63993000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
48540000
CY2023Q1 us-gaap Assets
Assets
4309147000
CY2022Q4 us-gaap Assets
Assets
4345355000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
38625000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
47690000
CY2023Q1 tdoc Accrued Liabilities And Other Liabilities Excluding Accrued Compensation Current
AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent
184642000
CY2022Q4 tdoc Accrued Liabilities And Other Liabilities Excluding Accrued Compensation Current
AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent
168693000
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
50900000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
81554000
CY2023Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
95930000
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
90457000
CY2023Q1 tdoc Advances From Financing Companies Current
AdvancesFromFinancingCompaniesCurrent
11247000
CY2022Q4 tdoc Advances From Financing Companies Current
AdvancesFromFinancingCompaniesCurrent
11375000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
381344000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
399769000
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1749000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1618000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
35927000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
38042000
CY2023Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
4117000
CY2022Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3872000
CY2023Q1 tdoc Advances From Financing Companies Noncurrent
AdvancesFromFinancingCompaniesNoncurrent
8037000
CY2022Q4 tdoc Advances From Financing Companies Noncurrent
AdvancesFromFinancingCompaniesNoncurrent
8082000
CY2023Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
50613000
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
50939000
CY2023Q1 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
1536134000
CY2022Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
1535288000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
163919394
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
162840360
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
164000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
163000
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
17409574000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
17358645000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-15077515000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-15008287000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-40997000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-42776000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
2291226000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
2307745000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4309147000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4345355000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
629244000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
565350000
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
190107000
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
187025000
CY2023Q1 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
176790000
CY2022Q1 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
133600000
CY2023Q1 us-gaap Selling Expense
SellingExpense
54490000
CY2022Q1 us-gaap Selling Expense
SellingExpense
58329000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
86985000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
87412000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
114145000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
104923000
CY2023Q1 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
5944000
CY2022Q1 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
4507000
CY2023Q1 us-gaap Restructuring Costs
RestructuringCosts
8102000
CY2022Q1 us-gaap Restructuring Costs
RestructuringCosts
0
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
69783000
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
58933000
CY2023Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2022Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
6600000000
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
706346000
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
7234729000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-77102000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6669379000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4907000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
724000
CY2023Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
3648000
CY2022Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-5480000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-68547000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6674135000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
681000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
388000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-69228000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-6674523000
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
1779000
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-5139000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-67449000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6679662000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.42
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-41.58
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
162922691
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
160532301
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
2307745000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
296000
CY2023Q1 tdoc Stock Issued During Period Value Vesting Of Restricted Stock Units
StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits
0
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
50634000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1779000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-69228000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
2291226000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
16045757000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3585000
CY2022Q1 tdoc Stock Issued During Period Value Vesting Of Restricted Stock Units
StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits
0
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
63963000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-5139000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-6674523000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
9142610000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-69228000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-6674523000
CY2023Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2022Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
6600000000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
69783000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
58933000
CY2023Q1 tdoc Depreciation Of Rental Equipment
DepreciationOfRentalEquipment
681000
CY2022Q1 tdoc Depreciation Of Rental Equipment
DepreciationOfRentalEquipment
770000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
3056000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
3173000
CY2023Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
9034000
CY2022Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
4591000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
46038000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
60436000
CY2023Q1 tdoc Deferred Income Tax Noncash Expense Benefit
DeferredIncomeTaxNoncashExpenseBenefit
-355000
CY2022Q1 tdoc Deferred Income Tax Noncash Expense Benefit
DeferredIncomeTaxNoncashExpenseBenefit
-2319000
CY2023Q1 tdoc Accretion Of Interest
AccretionOfInterest
845000
CY2022Q1 tdoc Accretion Of Interest
AccretionOfInterest
826000
CY2023Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
3522000
CY2022Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
14046000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
27842000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6165000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
18993000
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-10000000
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-2023000
CY2023Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
9939000
CY2022Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
6047000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-9132000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
492000
CY2023Q1 tdoc Increase Decrease In Accrued Liabilities And Other Current Liabilities Excluding Accrued Compensation
IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilitiesExcludingAccruedCompensation
15452000
CY2022Q1 tdoc Increase Decrease In Accrued Liabilities And Other Current Liabilities Excluding Accrued Compensation
IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilitiesExcludingAccruedCompensation
11706000
CY2023Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-32265000
CY2022Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-48819000
CY2023Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
5648000
CY2022Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
7479000
CY2023Q1 tdoc Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-2858000
CY2022Q1 tdoc Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-3626000
CY2023Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
129000
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-7000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
13156000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31747000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2363000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3913000
CY2023Q1 us-gaap Payments For Software
PaymentsForSoftware
43261000
CY2022Q1 us-gaap Payments For Software
PaymentsForSoftware
26918000
CY2023Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
0
CY2022Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-3264000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-45624000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-27567000
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
296000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3585000
CY2023Q1 tdoc Proceeds From Advances From Financing Companies
ProceedsFromAdvancesFromFinancingCompanies
3375000
CY2022Q1 tdoc Proceeds From Advances From Financing Companies
ProceedsFromAdvancesFromFinancingCompanies
2232000
CY2023Q1 tdoc Payments From Customers Against Advances From Financing Companies
PaymentsFromCustomersAgainstAdvancesFromFinancingCompanies
3548000
CY2022Q1 tdoc Payments From Customers Against Advances From Financing Companies
PaymentsFromCustomersAgainstAdvancesFromFinancingCompanies
3921000
CY2023Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
2731000
CY2022Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
3680000
CY2023Q1 tdoc Cash Related To Tax Withholding For Share Based Compensation Net
CashRelatedToTaxWithholdingForShareBasedCompensationNet
496000
CY2022Q1 tdoc Cash Related To Tax Withholding For Share Based Compensation Net
CashRelatedToTaxWithholdingForShareBasedCompensationNet
103000
CY2023Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
3000
CY2022Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-2863000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3353000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2816000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-29115000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-56498000
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-488000
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-538000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
918182000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
893480000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
888579000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
836444000
CY2023Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
346000
CY2022Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
261000
CY2023Q1 us-gaap Interest Paid
InterestPaid
194000
CY2022Q1 us-gaap Interest Paid
InterestPaid
7000
CY2023Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9.5pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">T</b><b style="font-weight:bold;">ELADOC HEALTH, INC. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Note 1. Organization and Description of Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">Teladoc Health, Inc., together with its subsidiaries, is referred to herein as “Teladoc Health,” or the “Company,” and is the global leader in whole person virtual care focusing on forging a new healthcare experience with better convenience, outcomes, and value around the world. The Company’s mission is to empower all people everywhere to live their healthiest lives by transforming the healthcare experience</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company was incorporated in the State of Texas in June 2002 and changed its state of incorporation to the State of Delaware in October 2008. Effective August 10, 2018, Teladoc, Inc. changed its corporate name to Teladoc Health, Inc. The Company’s principal executive office is located in Purchase, New York.</p>
CY2023Q1 tdoc Number Of Professional Associations Consolidated As Variable Interest Entities
NumberOfProfessionalAssociationsConsolidatedAsVariableInterestEntities
2
CY2023Q1 tdoc Number Of Professional Corporations Consolidated As Variable Interest Entities
NumberOfProfessionalCorporationsConsolidatedAsVariableInterestEntities
10
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. The Company bases its estimates on historical experience, current business and economic factors, and various other assumptions that the Company believes are necessary to form a basis for making judgments about the carrying values of assets and liabilities, the recorded amounts of revenue and expenses, and the disclosure of contingent assets and liabilities. The Company is subject to uncertainties such as the impact of future events, economic and political factors, and changes in the Company’s business environment; therefore, actual results could differ from these estimates. Accordingly, the accounting estimates used in the preparation of the Company’s condensed consolidated financial statements will change as new events occur, as more experience is acquired, as additional information is obtained and as the Company’s operating environment evolves. The Company believes that estimates used in the preparation of these condensed consolidated financial statements are reasonable; however, actual results could differ materially from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Changes in estimates are made when circumstances warrant. Such changes in estimates and refinements in estimation methodologies are reflected in the Condensed Consolidated Statement of Operations; if material, the effects of changes in estimates are disclosed in the Notes to Unaudited Condensed Consolidated Financial Statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Significant estimates and assumptions by management affect areas including the value and useful life of long-lived assets (including intangible assets), the value of goodwill, the capitalization and amortization of software development costs, deferred device and contract costs, allowances for sales and for doubtful accounts, and the accounting for business combinations. Other significant areas include revenue recognition (including performance guarantees), the accounting for income taxes, contingencies, litigation and related legal accruals, the accounting for stock-based compensation awards, and other items as described in the Summary of Significant Accounting policies in this Quarterly Report and in the 2022 Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p>
CY2022Q4 tdoc Deferred Device Cost And Other Noncurrent
DeferredDeviceCostAndOtherNoncurrent
8404000
CY2023Q1 tdoc Deferred Device Cost And Other
DeferredDeviceCostAndOther
43609000
CY2022Q4 tdoc Deferred Device Cost And Other
DeferredDeviceCostAndOther
38360000
CY2022Q4 tdoc Deferred Device Cost And Other
DeferredDeviceCostAndOther
38360000
CY2023Q1 tdoc Deferred Device Cost And Other Additions
DeferredDeviceCostAndOtherAdditions
16572000
CY2023Q1 tdoc Deferred Device Cost And Other Cost Of Revenue Recognized
DeferredDeviceCostAndOtherCostOfRevenueRecognized
-11323000
CY2023Q1 tdoc Deferred Device Cost And Other
DeferredDeviceCostAndOther
43609000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
629244000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
565350000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
629244000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
565350000
CY2023Q1 us-gaap Deferred Revenue
DeferredRevenue
100000000.0
CY2022Q1 us-gaap Deferred Revenue
DeferredRevenue
87100000
CY2023Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
5700000
CY2022Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
7600000
CY2023Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
61500000
CY2022Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
51600000
CY2023Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
87800000
CY2023Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
10600000
CY2023Q1 tdoc Deferred Device Cost And Other Current
DeferredDeviceCostAndOtherCurrent
26576000
CY2022Q4 tdoc Deferred Device Cost And Other Current
DeferredDeviceCostAndOtherCurrent
29956000
CY2023Q1 tdoc Deferred Device Cost And Other Noncurrent
DeferredDeviceCostAndOtherNoncurrent
17033000
CY2023Q1 tdoc Fair Value Assets And Liabilities Transfers Between Fair Value Measurement Levels Amount
FairValueAssetsAndLiabilitiesTransfersBetweenFairValueMeasurementLevelsAmount
0
CY2022 tdoc Fair Value Assets And Liabilities Transfers Between Fair Value Measurement Levels Amount
FairValueAssetsAndLiabilitiesTransfersBetweenFairValueMeasurementLevelsAmount
0
CY2023Q1 tdoc Inventory Raw Materials And Purchased Parts Gross
InventoryRawMaterialsAndPurchasedPartsGross
26403000
CY2022Q4 tdoc Inventory Raw Materials And Purchased Parts Gross
InventoryRawMaterialsAndPurchasedPartsGross
30126000
CY2023Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
934000
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
433000
CY2023Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
26338000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
31977000
CY2023Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7874000
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
6194000
CY2023Q1 us-gaap Inventory Net
InventoryNet
45801000
CY2022Q4 us-gaap Inventory Net
InventoryNet
56342000
CY2023Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2467800000
CY2023Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
651852000
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1815948000
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2421251000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
584486000
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
77526000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
63159000
CY2023Q1 tdoc Deferred Device Cost And Other Current
DeferredDeviceCostAndOtherCurrent
26576000
CY2022Q4 tdoc Deferred Device Cost And Other Current
DeferredDeviceCostAndOtherCurrent
29956000
CY2023Q1 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
25099000
CY2022Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
25091000
CY2023Q1 us-gaap Other Assets Current
OtherAssetsCurrent
7145000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
12104000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
136346000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
130310000
CY2023Q1 us-gaap Goodwill
Goodwill
1073190000
CY2023Q1 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
13400000000
CY2022Q3 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
12300000000
CY2022Q4 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1836765000
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
66900000
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
56600000
CY2023Q1 us-gaap Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
16600000
CY2022Q1 us-gaap Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
6700000
CY2023Q1 tdoc Cloud Computing Costs Net
CloudComputingCostsNet
32500000
CY2022Q4 tdoc Cloud Computing Costs Net
CloudComputingCostsNet
25400000
CY2023Q1 tdoc Cloud Computing Expense
CloudComputingExpense
800000
CY2022Q1 tdoc Cloud Computing Expense
CloudComputingExpense
300000
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
14158000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
10152000
CY2023Q1 tdoc Accrued Consulting And Customer Service Fees Current
AccruedConsultingAndCustomerServiceFeesCurrent
22345000
CY2022Q4 tdoc Accrued Consulting And Customer Service Fees Current
AccruedConsultingAndCustomerServiceFeesCurrent
16407000
CY2023Q1 tdoc Other Current Liabilities Clients Guarantees
OtherCurrentLiabilitiesClientsGuarantees
6909000
CY2022Q4 tdoc Other Current Liabilities Clients Guarantees
OtherCurrentLiabilitiesClientsGuarantees
4145000
CY2023Q1 us-gaap Interest Payable Current
InterestPayableCurrent
5811000
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
1480000
CY2023Q1 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
4694000
CY2022Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
3817000
CY2023Q1 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
5125000
CY2022Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
5981000
CY2023Q1 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
3136000
CY2022Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
0
CY2023Q1 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
40427000
CY2022Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
35055000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
12958000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
13592000
CY2023Q1 tdoc Other Current Liabilities Acquisition And Integration
OtherCurrentLiabilitiesAcquisitionAndIntegration
13272000
CY2022Q4 tdoc Other Current Liabilities Acquisition And Integration
OtherCurrentLiabilitiesAcquisitionAndIntegration
10183000
CY2023Q1 tdoc Other Current Liabilities Accrued Rebates
OtherCurrentLiabilitiesAccruedRebates
17831000
CY2022Q4 tdoc Other Current Liabilities Accrued Rebates
OtherCurrentLiabilitiesAccruedRebates
14542000
CY2023Q1 tdoc Other Current Liabilities Staff Augmentation
OtherCurrentLiabilitiesStaffAugmentation
4479000
CY2022Q4 tdoc Other Current Liabilities Staff Augmentation
OtherCurrentLiabilitiesStaffAugmentation
3391000
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
33497000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
49948000
CY2023Q1 tdoc Accrued Liabilities And Other Liabilities Excluding Accrued Compensation Current
AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent
184642000
CY2022Q4 tdoc Accrued Liabilities And Other Liabilities Excluding Accrued Compensation Current
AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent
168693000
CY2023Q1 us-gaap Convertible Debt
ConvertibleDebt
1536134000
CY2022Q4 us-gaap Convertible Debt
ConvertibleDebt
1535288000
CY2023Q1 tdoc Advances From Financing Companies Customer Payments Due Current
AdvancesFromFinancingCompaniesCustomerPaymentsDueCurrent
8908000
CY2023Q1 tdoc Advances From Financing Companies Customer Payments Due Year One
AdvancesFromFinancingCompaniesCustomerPaymentsDueYearOne
7382000
CY2023Q1 tdoc Advances From Financing Companies Customer Payments Due Year Two
AdvancesFromFinancingCompaniesCustomerPaymentsDueYearTwo
2903000
CY2023Q1 tdoc Advances From Financing Companies Customer Payments Due Year Three
AdvancesFromFinancingCompaniesCustomerPaymentsDueYearThree
91000
CY2023Q1 tdoc Advances From Financing Companies Customer Payments Due
AdvancesFromFinancingCompaniesCustomerPaymentsDue
19284000
CY2023Q1 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
11783000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
11176000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
8615000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
7547000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
5436000
CY2023Q1 tdoc Lessee Operating Lease Liability Payments Due Year Five And After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive
13375000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
57932000
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
9047000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
48885000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
12958000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
35927000
CY2023Q1 us-gaap Restructuring Costs
RestructuringCosts
8100000
CY2022Q4 us-gaap Restructuring Reserve
RestructuringReserve
4043000
CY2023Q1 us-gaap Restructuring Charges
RestructuringCharges
7640000
CY2023Q1 us-gaap Payments For Restructuring
PaymentsForRestructuring
6513000
CY2023Q1 us-gaap Restructuring Reserve
RestructuringReserve
5170000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
6278157
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4243934
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
27.79
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y1M6D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
19541000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
20431
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
23.65
CY2023Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
28127
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
10.51
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
475000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
40725
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
47.20
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4195513
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
27.69
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y9M14D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
23800000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4195513
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
27.69
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P5Y9M14D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
23800000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2716055
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
23.11
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y11M8D
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
23711000
CY2023Q1 tdoc Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Total Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue
200000
CY2022Q1 tdoc Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Total Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue
1600000
CY2022Q1 tdoc Earnings Before Interest Taxes Depreciation And Amortization
EarningsBeforeInterestTaxesDepreciationAndAmortization
54497000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
46038000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
60436000
CY2023Q1 tdoc Share Based Payment Arrangement Expense Reversal Due To Restructuring
ShareBasedPaymentArrangementExpenseReversalDueToRestructuring
4500000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
700000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
400000
CY2023Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2023Q1 us-gaap Revenues
Revenues
629244000
CY2022Q1 us-gaap Revenues
Revenues
565350000
CY2023Q1 tdoc Earnings Before Interest Taxes Depreciation And Amortization
EarningsBeforeInterestTaxesDepreciationAndAmortization
52765000
CY2023Q1 tdoc Earnings Before Interest Taxes Depreciation And Amortization
EarningsBeforeInterestTaxesDepreciationAndAmortization
52765000
CY2022Q1 tdoc Earnings Before Interest Taxes Depreciation And Amortization
EarningsBeforeInterestTaxesDepreciationAndAmortization
54497000
CY2023Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2022Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
6600000000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4907000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
724000
CY2023Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
3648000
CY2022Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-5480000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
69783000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
58933000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
46038000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
60436000
CY2023Q1 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
5944000
CY2022Q1 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
4507000
CY2023Q1 us-gaap Restructuring Costs
RestructuringCosts
8102000
CY2022Q1 us-gaap Restructuring Costs
RestructuringCosts
0
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-68547000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6674135000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
681000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
388000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-69228000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-6674523000
CY2023Q1 us-gaap Noncurrent Assets
NoncurrentAssets
29791000
CY2022Q4 us-gaap Noncurrent Assets
NoncurrentAssets
29641000

Files In Submission

Name View Source Status
0001558370-23-007654-index-headers.html Edgar Link pending
0001558370-23-007654-index.html Edgar Link pending
0001558370-23-007654.txt Edgar Link pending
0001558370-23-007654-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tdoc-20230331.xsd Edgar Link pending
tdoc-20230331x10q.htm Edgar Link pending
tdoc-20230331x10q006.jpg Edgar Link pending
tdoc-20230331x10q007.jpg Edgar Link pending
tdoc-20230331xex31d1.htm Edgar Link pending
tdoc-20230331xex31d2.htm Edgar Link pending
tdoc-20230331xex32d1.htm Edgar Link pending
tdoc-20230331xex32d2.htm Edgar Link pending
tdoc-20230331_cal.xml Edgar Link unprocessable
tdoc-20230331_lab.xml Edgar Link unprocessable
tdoc-20230331_pre.xml Edgar Link unprocessable
tdoc-20230331_def.xml Edgar Link unprocessable
tdoc-20230331x10q_htm.xml Edgar Link completed